Tag: EcoR1

ElevateBio, LLC (ElevateBio), a technology-driven company focused on cell and gene therapies, has closed its $401 million Series D financing. “We have made significant strides in scaling our technologies and end-to-end capabilities in our pursuit to become the world’s most indispensable cell and gene therapy technology company. We are thrilled…

Plasmids LentiCRISPRv2 (Addgene; 52961) was purchased from Addgene (Cambridge, MA, USA). For HTT gene suppression, LentiCRISPR v2 plasmid with U6 promoter driving sgRNA expression and EF-1 alpha promoter driving the expression of Puromycin-T2A-HA-NLS-dCas9-NLS (or Puromycin-T2A-Flag-NLS-Cas9-NLS) was used. The sgRNA-Cas9 and sgRNA-dCas9 constructs were generated by cloning the CAG repeat-targeting sgRNA…

Transcribed image text: You are trying to clone a ribosomal 16s rRNA gene fragment from soil bacteria that has been PCR amplified. This is the resulting image after electrophoresis. Match up the type of DNA to the corresponding letter (letters are positioned just to the right of the corresponding stained…

Question Description If a long linear dsDNA having blunt ends with 5’GAATTC3′ 3’CTTAGG5′ sequences at four places is cleaved by using EcoR1, how many DNA fragments are formed with cohesive ends on both sides? 1)5 2)4 3)3 4)2? for NEET 2022 is part of NEET preparation. The Question and…

Using these strains, it is possible to integrate plasmids that carry the complementary ΦC31 att site onto the chromosome (attP, in this figure). Because the mtDNA codes for key OXPHOS polypeptides, genetic alterations in the mtDNA will affect energy metabolism. Proc Natl Acad Sci U S A. 1969 Jun;98(3):1248-57 eCollection…

Apply here Chinook Therapeutics Job Description: Computational Biologist Company: Chinook Therapeutics is a clinical-stage biotechnology company developing precision medicines for patients with kidney diseases. We apply our proprietary research platform to discover and develop therapeutics with novel mechanisms of action against key kidney disease pathways. Our development focus is on…